Treatment satisfaction with Omnipod DASH in adults with type 1 diabetes: A non-blinded 1:1 randomized controlled trial.
Yee Wen KongCheng Yi YuanKaterina KiburgKatrin BrownSteven TrawleyAndi PartoviKerryn RoemCecilia PhamNatalie HarrisonSpiros FourlanosElif I EkinciDavid Norman O'NealPublished in: The Journal of clinical endocrinology and metabolism (2024)
Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG which was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.